U.S. market Closed. Opens in 1 day 9 hours 37 minutes

RLMD | Relmada Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 0.3430 - 0.3800
52 Week Range 0.3420 - 7.22
Beta -0.10
Implied Volatility 311.33%
IV Rank 95.04%
Day's Volume 423,979
Average Volume 772,898
Shares Outstanding 30,174,200
Market Cap 10,950,217
Sector Healthcare
Industry Biotechnology
IPO Date 2014-06-20
Valuation
Profitability
Growth
Health
P/E Ratio -0.13
Forward P/E Ratio N/A
EPS -2.86
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 20
Country USA
Website RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
*Chart delayed
Analyzing fundamentals for RLMD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see RLMD Fundamentals page.

Watching at RLMD technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on RLMD Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙